发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Ocular toxicities in chimeric antigen receptor T-cell therapy: a real-world study leveraging FAERS database. 嵌合抗原受体 T 细胞疗法的眼部毒性：一项利用 FAERS 数据库进行的真实世界研究。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-21 DOI: 10.2217/imt-2023-0220
Na Zhao, Fangyuan Hu, Yinghong Zhai, Xia Ye, Yiming Ruan, Zhen Liu, Zhiyan Wang, Wei Shen, Lei Yuan
{"title":"Ocular toxicities in chimeric antigen receptor T-cell therapy: a real-world study leveraging FAERS database.","authors":"Na Zhao, Fangyuan Hu, Yinghong Zhai, Xia Ye, Yiming Ruan, Zhen Liu, Zhiyan Wang, Wei Shen, Lei Yuan","doi":"10.2217/imt-2023-0220","DOIUrl":"10.2217/imt-2023-0220","url":null,"abstract":"<p><p><b>Aim:</b> The purpose of this study was to comprehensively explore the ocular toxicity associated with chimeric antigen receptor (CAR) T-cell therapy. <b>Materials & methods:</b> Data were assembled from the US FDA's Adverse Event Reporting System (FAERS) database from 2017 to 2023. Information component and reporting odds ratio methods were used for signal detection in total/categorized CAR T-cell therapy. <b>Results:</b> A total of 17 positive signals (preferred term) were detected, yet none of them were documented in the product information. Some adverse events were with death outcomes and overlapped a lot with cytokine-release syndrome. <b>Conclusion:</b> The ocular adverse events associated with CAR-T cell therapy are noteworthy, and it is imperative to maintain increased alertness and institute early intervention strategies.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"161-172"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncolytic viruses in lung cancer treatment: a review article. 肺癌治疗中的溶瘤病毒：综述文章。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-19 DOI: 10.2217/imt-2023-0124
Hanie Sakhi, Mohadeseh Arabi, Amir Ghaemi, Abolfazl Movafagh, Mojgan Sheikhpour
{"title":"Oncolytic viruses in lung cancer treatment: a review article.","authors":"Hanie Sakhi, Mohadeseh Arabi, Amir Ghaemi, Abolfazl Movafagh, Mojgan Sheikhpour","doi":"10.2217/imt-2023-0124","DOIUrl":"10.2217/imt-2023-0124","url":null,"abstract":"<p><p>Lung cancer has a high morbidity rate worldwide due to its resistance to therapy. So new treatment options are needed to improve the outcomes of lung cancer treatment. This study aimed to evaluate the effectiveness of oncolytic viruses (OVs) as a new type of cancer treatment. In this study, 158 articles from PubMed and Scopus from 1994 to 2022 were reviewed on the effectiveness of OVs in the treatment of lung cancer. The oncolytic properties of eight categories of OVs and their interactions with treatment options were investigated. OVs can be applied as a promising immunotherapy option, as they are reproduced selectively in different types of cancer cells, cause tumor cell lysis and trigger efficient immune responses.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"75-97"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-tumor immunity and vitiligo: from immune-related adverse reactions to protection from cancer. 抗肿瘤免疫与白癜风：从免疫相关不良反应到防癌保护。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-07-26 DOI: 10.1080/1750743X.2024.2377954
Roberto Mazzetto, Alvise Sernicola, Paola Miceli, Jacopo Tartaglia, Christian Ciolfi, Mauro Alaibac
{"title":"Anti-tumor immunity and vitiligo: from immune-related adverse reactions to protection from cancer.","authors":"Roberto Mazzetto, Alvise Sernicola, Paola Miceli, Jacopo Tartaglia, Christian Ciolfi, Mauro Alaibac","doi":"10.1080/1750743X.2024.2377954","DOIUrl":"10.1080/1750743X.2024.2377954","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"841-843"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141763974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis. ixekizumab在治疗非放射性轴性脊柱关节炎中的作用。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-03-21 DOI: 10.2217/imt-2023-0015
Bora Nam, Tae-Hwan Kim
{"title":"The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis.","authors":"Bora Nam, Tae-Hwan Kim","doi":"10.2217/imt-2023-0015","DOIUrl":"10.2217/imt-2023-0015","url":null,"abstract":"<p><p>Nonradiographic axial spondyloarthritis (nr-axSpA) is a subtype of SpA with undeveloped definite radiographic sacroiliitis. Tumor necrosis factor inhibitors have demonstrated effectiveness in nr-axSpA patients who do not respond to first-line therapy. More recently, accumulated data from genetic, experimental, and clinical studies revealed that IL-17 is a key player in the pathogenesis of SpA, leading to development of new biologics directly inhibiting IL-17. Among them, ixekizumab is a high-affinity monoclonal antibody that selectively targets IL-17A and has exhibited significant efficacy and acceptable safety profiles in the treatment of nr-axSpA. The aim of this paper is to narratively review the recent insights of IL-17 in the pathogenesis of axSpA and discuss the effectiveness and safety of ixekizumab in treatment of nr-axSpA.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"569-580"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allogeneic CAR-T cells for cancer immunotherapy. 用于癌症免疫疗法的异体 CAR-T 细胞。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-10-08 DOI: 10.1080/1750743X.2024.2408048
Xinfeng Chen, Yaoxin Gao, Yi Zhang
{"title":"Allogeneic CAR-T cells for cancer immunotherapy.","authors":"Xinfeng Chen, Yaoxin Gao, Yi Zhang","doi":"10.1080/1750743X.2024.2408048","DOIUrl":"10.1080/1750743X.2024.2408048","url":null,"abstract":"<p><p>Autologous chimeric antigen receptor (CAR)-modified T (CAR-T) cell therapy has displayed high efficacy in the treatment of hematological malignancies. Up to now, 11 autologous CAR-T cell products have been approved for the management of malignancies globally. However, the application of autologous CAR-T cell therapy has many individual limitations, long time-consuming, highly cost, and the risk of manufacturing failure. Indeed, some patients would not benefit from autologous CAR-T cell products because of rapid disease progression. Allogeneic CAR-T cells especially universal CAR-T (U-CAR-T) cell therapy are superior to these challenges of autologous CAR-T cells. In this review, we describe basic study and clinical trials of U-CAR-T cell therapeutic methods for malignancies. In addition, we summarize the problems encountered and potential solutions.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1079-1090"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alpha/beta-defensins influence on the humoral immunity and complications in cancer of the oral cavity and oropharynx. α/β-防御素对体液免疫和口腔及口咽癌并发症的影响。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI: 10.1080/1750743X.2024.2376517
Halyna Hirna, Dmitry Maltsev
{"title":"Alpha/beta-defensins influence on the humoral immunity and complications in cancer of the oral cavity and oropharynx.","authors":"Halyna Hirna, Dmitry Maltsev","doi":"10.1080/1750743X.2024.2376517","DOIUrl":"10.1080/1750743X.2024.2376517","url":null,"abstract":"<p><p><b>Aim:</b> Patients with cancer of the oral cavity and oropharynx (COCO) often exhibit signs of immunosuppression, affecting their prognosis. Understanding the dynamics of humoral immunity in these patients during chemoradiation therapy is crucial for developing effective treatments.<b>Materials & methods:</b> This prospective study included 105 COCO patients undergoing different treatment regimens, with or without alpha/beta-defensins therapy. Serum concentrations of IgG, IgM, IgA and salivary sIgA were analyzed. Patients were divided into five groups based on treatment protocols.<b>Results & conclusion:</b> Treatment variations impacted serum immunoglobulin levels, notably in Group III, whose patients received radiation treatment and immunotherapy with higher alpha/beta-defensins doses. Significant IgG changes correlated with oral mucositis risk and outcomes. Further trials are necessary for validation and clinical application.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"869-878"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of nemolizumab in the treatment of atopic dermatitis for the adult population. 奈莫利单抗在成人特应性皮炎治疗中的作用。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-08-09 DOI: 10.1080/1750743X.2024.2383554
Stuti Prajapati, Joseph P Flemming, Danyaal Khan, Haowei Han, Brian How, Suzanne Sirota Rozenberg, Steven R Feldman
{"title":"The role of nemolizumab in the treatment of atopic dermatitis for the adult population.","authors":"Stuti Prajapati, Joseph P Flemming, Danyaal Khan, Haowei Han, Brian How, Suzanne Sirota Rozenberg, Steven R Feldman","doi":"10.1080/1750743X.2024.2383554","DOIUrl":"10.1080/1750743X.2024.2383554","url":null,"abstract":"<p><p>Atopic dermatitis (AD) often requires long-term treatment that may be associated with adverse effects. This review aims to characterize nemolizumab as a treatment for AD in adults. A literature search was performed to assess nemolizumab's role in moderate-to-severe AD in adults. Currently, clinical trials are being conducted to evaluate the clinical efficacy, safety profile and optimal dosing of nemolizumab for adults with moderate-to-severe AD. The most common adverse effects include nasopharyngitis, AD exacerbation and increased blood creatinine phosphokinase. Recent data from clinical trials suggest nemolizumab may be an acceptable treatment in adults with moderate-to-severe AD.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"925-935"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics. 原发性免疫缺陷病的免疫球蛋白疗法（第一部分）：了解药物动力学。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-09-26 DOI: 10.1080/1750743X.2024.2382081
Iftekhar Mahmood, Zhaoyang Li
{"title":"Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics.","authors":"Iftekhar Mahmood, Zhaoyang Li","doi":"10.1080/1750743X.2024.2382081","DOIUrl":"10.1080/1750743X.2024.2382081","url":null,"abstract":"<p><p>Immunoglobulin G (IgG) therapies have been used for decades as standard treatment for patients with primary antibody deficiencies. Monitoring the pharmacokinetics (PK) of IgG is a key component in guiding treatment regimens. Despite the wealth of clinical experience, substantial gaps exist in our understanding of the true nature of IgGs and their disposition in humans. Furthermore, intrinsic and extrinsic factors may alter the PK of IgG, necessitating an individualized approach for patients. A comprehensive literature review was performed in order to summarize the PK of IgGs, examine the mechanisms of IgG disposition (including catabolism), outline considerations for special patient populations and discuss knowledge gaps and future perspectives for improving our understanding of IgG PK in relation to the individualized treatment paradigm.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"16 13","pages":"879-894"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142345785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. 用嵌合抗原受体 T 细胞疗法治疗 Epstein-Barr 病毒阳性弥漫大 B 细胞淋巴瘤患者的嗜血细胞淋巴组织细胞增多症。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-10-17 DOI: 10.1080/1750743X.2024.2409622
Ana Maria Meireles, Gloria Iacoboni, Leonardo Maia Moço, Inês Ramos, Gil Brás, Júlia Azevedo, Ângelo Rodrigues, Cláudia Moreira, Mário Mariz
{"title":"Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.","authors":"Ana Maria Meireles, Gloria Iacoboni, Leonardo Maia Moço, Inês Ramos, Gil Brás, Júlia Azevedo, Ângelo Rodrigues, Cláudia Moreira, Mário Mariz","doi":"10.1080/1750743X.2024.2409622","DOIUrl":"10.1080/1750743X.2024.2409622","url":null,"abstract":"<p><p>With the advent of chimeric antigen receptors T-cell therapy, understanding their role in the development of hemophagocytic lymphohistiocytosis has become increasingly complex. We describe a case of a young patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma, who was treated with axicabtagene ciloleucel. The patient developed progressive cytopenia and, on Day 73 post-infusion, met criteria for hemophagocytic lymphohistiocytosis. Bone marrow evaluation revealed hemophagocytosis without evidence of clonal B cells. The patient was treated with tocilizumab, dexamethasone, etoposide and anakinra, which eventually led to improvement. Unfortunately, the patient succumbed to an infection. Disease progression was confirmed posthumously.This case report explores the differential diagnosis of hyperinflammatory syndromes following chimeric antigen receptor T-cell therapy and highlights the reduced efficacy of this treatment in patients with a T-cell/histiocyte-rich background.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1105-1111"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature. Tislelizumab 引起的细胞因子释放综合征：首例病例报告和文献综述。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-11-21 DOI: 10.1080/1750743X.2024.2422814
Haobo Yin, Yanwen Diao, Zhen Zheng, Qian Dong, Jingdong Zhang
{"title":"Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature.","authors":"Haobo Yin, Yanwen Diao, Zhen Zheng, Qian Dong, Jingdong Zhang","doi":"10.1080/1750743X.2024.2422814","DOIUrl":"10.1080/1750743X.2024.2422814","url":null,"abstract":"<p><p>Cytokine release syndrome (CRS) is an uncommon but deadly side effect of immune checkpoint inhibitors (ICIs). ICIs are presently an increasingly important therapy option for malignant tumors, but there are limited treatments available for CRS. We present a case of a 72-year-old man who received one cycle of ICI coupled with cisplatin and albumin-binding paclitaxel therapy for a locally advanced right lung adenocarcinoma. Following an abrupt onset of dyspnea, the patient underwent a quick physical examination, blood tests and was diagnosed with CRS. After prompt initiation of glucocorticoid pulse treatment, the symptoms relieved. The case illustrates the management of severe CRS following ICI therapy while highlighting the uncommon and potentially fatal immune-related side effects.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1113-1122"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信